Abemaciclib: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib]. | Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib]. | ||
<scene name='10/1002442/Overall/2'>The X-ray co-crystal structure of human CDK6 and Abemaciclib</scene> ([[5l2s]]). | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||